Sign In
Buy CLNN
$5.76
-0.110 (-1.87%)
At Close: Jun 03, 2026
Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates
10:10am, Thursday, 14'th May 2026
Clene Inc. (CLNN) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.5 per share a year ago.
Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
08:00am, Thursday, 14'th May 2026
After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8 ® under the accelerated approval pathway in the third quarter of 2026 In January 2026, Clene completed an
Clene Announces $7 Million Underwritten Offering of Common Stock
08:45am, Tuesday, 05'th May 2026
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary, Clene Nanomedicine, Inc., a
Clene to Present at Upcoming May Conferences
08:00am, Tuesday, 05'th May 2026
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage bio
Clene Stock Jumps After FDA Opens Door To Accelerated Approval For ALS Drug
11:22am, Monday, 04'th May 2026
Clene Inc. (NASDAQ:CLNN) shares are up 6.68% on Monday as the company is filing for accelerated approval of its ALS treatment following a constructive meeting with the FDA.
After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS
08:00am, Monday, 04'th May 2026
FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway” for CNM-Au8 based on neurofilament light (NfL) biomark
Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells $49,587.20 in Stock
05:14am, Monday, 20'th Apr 2026
Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 7,748 shares of the stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $6.40,
Clene (NASDAQ:CLNN) Major Shareholder Sells $41,303.52 in Stock
05:14am, Monday, 20'th Apr 2026
Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 6,374 shares of the company's stock in a transaction dated Wednesday, April 15th. The stock was sold at an average p
Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells $161,007.20 in Stock
04:26am, Monday, 20'th Apr 2026
Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 25,040 shares of Clene stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $6
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
08:00am, Thursday, 12'th Mar 2026
In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8® data submitted; Clene expects formal written meeting minutes early in the second quarter 2026
Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts
08:00am, Tuesday, 24'th Feb 2026
SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine Inc., a c
Contrasting Ventyx Biosciences (NASDAQ:VTYX) & Clene (NASDAQ:CLNN)
02:05am, Sunday, 22'nd Feb 2026
Ventyx Biosciences (NASDAQ: VTYX - Get Free Report) and Clene (NASDAQ: CLNN - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies
Clene Inc. (NASDAQ:CLNN) Receives $32.60 Consensus Target Price from Analysts
01:57am, Friday, 20'th Feb 2026
Clene Inc. (NASDAQ: CLNN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst
Clene to Present at the Emerging Growth Conference
08:30am, Thursday, 19'th Feb 2026
SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biophar
Brokerages Set Clene Inc. (NASDAQ:CLNN) PT at $32.60
01:18am, Monday, 26'th Jan 2026
Shares of Clene Inc. (NASDAQ: CLNN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven ratings firms that are covering the stock, MarketBeat reports. One research
